Antiretroviral treatments-related lipodystrophy syndrome: Clinico-pathological findings;Le syndrome lipodystrophique associé aux traitements antirétroviraux: Aspects anatomo-cliniques

Annales de Pathologie

Volumn 25, Issue 4, 2005, Pages 309-317

  Lassalle, Sandra ^a   Cervera, Pascale ^b   Hofman, Véronique ^a   Mari, Mireille ^a   Dellamonica, Pierre ^c   Hofman, Paul ^a  

^a PASTEUR HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Adipose tissue; AIDS; Antiretroviral therapy; HIV; Mitochondria

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ABDOMEN; ARTICLE; BREAST; BUTTOCK; CERVICAL SPINE; CLINICAL FEATURE; CUSHING SYNDROME; DRUG EFFICACY; FACE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LACTIC ACIDEMIA; LIMB; LIPOATROPHY; LIPODYSTROPHY; LIPOGRANULOMA; LIPOHYPERTROPHY; SKIN BIOPSY; SKIN FIBROSIS; SUBCUTANEOUS FAT; WASTING SYNDROME;

EID: 27944511806     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0242-6498(05)80135-x     Document Type: Article

References (57)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
2. Hofman P. Que reste t-il de la pathologie liée au VIH? Ann Pathol 2004; S1: 29-30.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. « Buffalo hump » in men with HIV infection. Lancet 1998; 351: 867-70.
5. Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet 1998; 351: 1736.
6. Cossarizza A, Mussini C, Vigano A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? Bioessays 2001; 23: 1070-80.
7. Cossarizza A, Trojano L, Mussini C. Mitochondria and HIV infection: the first decade. J Biol Regul Homeost Agents 2002; 16: 18-24.
8. Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999; 354: 1046-7.
9. Roge BT, Calbet JA, Moller K, Ullum H, Hendel HW, Gerstoft J et al. Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels. AIDS 2002; 16: 973-82.
10. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimuzu S. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801-9.
11. Zaera MC, Miro O, Pedrol E, Soler A, Picon M, Cardellach F et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15: 1643-51.
12. Kolter DP. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy. AIDS Read 2003; 13S: S5-S13.
13. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet 1999; 353: 1244.
14. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes, targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004; 9: 161-77.
15. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 1999; 353: 1243-4.
16. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30: S135-42.
17. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: 25-32.
18. Carr A. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-35.
19. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population based cohort. J Acquir Immune Defic Syndr 2002; 30: 440-7.
20. Jacquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E et al. Clinical and metabolic presentation of the lipodystrophy syndrome in HIV-infected children. AIDS 2000; 14: 2143-4.
21. Miller J, Carr A, Smith D, Emery S, Law MG, Grey P, Cooper DA. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000; 14: 2406-7.
22. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with AIDS infection. AIDS 1999; 13: 2493-505.
23. Saint-Marc T, Partisani M, Poizot Martin I, Bruno F, Rouviere O, Lang JM et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
24. Tien PC, Cole SR, Williams CM, Li R, Justman JE, Cohen MH et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003; 34: 461-6.
25. Gervasoni C, Ridolfo AL, Trifiro G et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465-72.
26. McComsey GA, Ward DJ, Hessenthaler SM, Senasion MG, Shalit P, Lonergan JT et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
27. European paedriatric lipodystrophy group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18: 1443-51.
28. Taylor P, Worell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004; 114: 235-42.
29. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27-31.
30. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chislom DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093-9.
31. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir immune Defic Syndr 2001; 27: 443-9.
32. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002; 283: 332-7.
33. Van der Valk M, Bisschop PH, Romjin JA, Ackermans MT, Lange JM, Endert E et al. Lipodystrophy in HIV-1 positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001; 15: 2093-100.
34. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV protease-inhibitor-associated lipodystrohy, hyperlipidaemia, and diabetes mellitus. Lancet 1999; 353: 2893-99.
35. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003; S2: 85-90.
36. Johnson JA, Albu JB, Engelson ES, Fried SK, Inada Y, Ionescu G et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286: 261-71.
37. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1 infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-31.
38. Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13: 2261-7.
39. Fessel WJ, Follansbee SB, Barker B. Ultrastructural findings consistent with brown adipocytes in buffalo humps of HIV-positive patients with fat redistribution syndrome. Antiviral Therapy 2000; 55: 25.
40. Lloreta J, Domingo P, Pujol RM, Arroyo JA, Baixeras N, Matias-Guiu X et al. Ultrastructure features of highly active antiretroviral therapy-associated partial lipodystrophy. Virchows Arch 2002; 441: 599-604.
41. Panse I, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E, Saiag P. Lipodystrophy associated with protease inhibitors. Br J Dermatol 2000; 142: 496-500.
42. Pujol RM, Domingo P, Matias-Guiu X, Francia E, Sanbeat MA, Alomar A et al. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol 2000; 42: 193-8.
43. Schindler J, Spooner k, Decker C. Buffalo humps associated with protease inhibitors. Ann Intern Med 1998; 129: 164.
44. Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9: 555-64.
45. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-38.
46. Levy Y, George J, Yona E, Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis and complement dysregulation. An autoimmune phenomenon. Immunol Res 1998; 18: 55-60.
47. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311-2.
48. Van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ et al. Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV infection. AIDS 2001; 15: 847-55.
49. Liang J-S, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7: 1327-31.
50. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002; 16: 859-63,
51. Behrens GMN, Boerner AR, Weber K, van der Hoff J, Ockenga J, Brabant G et al. Impaired glucose phosphorylation and transport in skeletal muscle causes insulin resistance in HIV-1 infected patients with lipodystrophy. J Clin Invest 2002; 110: 1319-27.
52. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-88.
53. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17: 2437-44.
54. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-16.
55. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
56. Bienvenu L, Burel F, Hofman V, Itchai C, Amaro J, Hofman P. Une étiologie rare de stéatose hépatique avec acidose lactique: la toxicité des analogues nucléosidiques anti-viraux. Ann Pathol 2001; 21: 160-3.
57. McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003; 13: 539-42.